Recent News for OGEN - Oragenics, Inc.

Date Title
Oct 2 OGEN: Phase 2 Trial of AG013 More Than 2/3rd Enrolled…
Sep 30 Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
Sep 29 The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear
Sep 25 Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients
Sep 23 Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress
Sep 10 Who Has Been Buying Oragenics, Inc. (NYSEMKT:OGEN) Shares?
Sep 6 Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference
Aug 20 Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium
Aug 15 The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings
Jul 10 Oragenics, Inc. (NYSEMKT:OGEN): What Does Its Beta Value Mean For Your Portfolio?
Jun 25 Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium
Jun 17 Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action
Jun 7 OGEN: New Pre-Clinical Data Shows Lantibiotic OG253 Safe and Well Tolerated…
May 20 Oragenics up 12% on advancement of oral mucositis candidate
May 20 Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis
May 13 Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract
Apr 24 Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%
Back to the Main OGEN Page...